Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study

<b>Background/Objectives:</b> Cardiovascular complications are a leading cause of premature mortality in patients with acromegaly. Copeptin (CPP) correlates strongly with plasma osmolality and is regulated by non-osmotic stimuli involved in the pathophysiology of cardiovascular disease....

Full description

Saved in:
Bibliographic Details
Main Authors: Martyna Strzelec, Eliza Kubicka, Justyna Kuliczkowska-Płaksej, Katarzyna Kolačkov, Łucja Janek, Marek Bolanowski, Aleksandra Jawiarczyk-Przybyłowska
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/3/666
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850089937880219648
author Martyna Strzelec
Eliza Kubicka
Justyna Kuliczkowska-Płaksej
Katarzyna Kolačkov
Łucja Janek
Marek Bolanowski
Aleksandra Jawiarczyk-Przybyłowska
author_facet Martyna Strzelec
Eliza Kubicka
Justyna Kuliczkowska-Płaksej
Katarzyna Kolačkov
Łucja Janek
Marek Bolanowski
Aleksandra Jawiarczyk-Przybyłowska
author_sort Martyna Strzelec
collection DOAJ
description <b>Background/Objectives:</b> Cardiovascular complications are a leading cause of premature mortality in patients with acromegaly. Copeptin (CPP) correlates strongly with plasma osmolality and is regulated by non-osmotic stimuli involved in the pathophysiology of cardiovascular disease. Mid-regional proadrenomedullin (MR-proADM), synthesized mainly in the adrenal medulla, vascular endothelial cells, and the heart, has vasodilatory effects. The study aimed to assess two cardiovascular biomarkers (CPP and MR-proADM) in acromegaly patients in relation to disease activity and compare findings with a control group. <b>Methods:</b> The study examined CPP and MR-proADM levels alongside hormonal and biochemical parameters and cardiovascular and metabolic disease prevalence in 53 acromegaly patients and 26 controls. <b>Results:</b> No significant differences in CPP or MR-proADM concentrations were observed between the two groups. However, a positive correlation occurred between growth hormone (GH) and CPP concentrations, and there was a negative correlation between fasting glucose and CPP concentrations in acromegaly patients. The study also found a positive correlation between low-density lipoprotein (LDL) cholesterol and MR-proADM concentrations and between high-density lipoprotein (HDL) cholesterol and MR-proADM levels in the study group. Moreover, atherogenic dyslipidemia was significantly more common in the active form of acromegaly and pituitary macroadenoma patients than in the control group. Acromegaly patients had significantly higher fasting glucose and fasting insulin levels compared to controls, and the homeostasis model assessment of the insulin resistance (HOMA-IR) index was significantly lower in the study group than in the controls. <b>Conclusions:</b> Neither CPP or MR-proADM are significant diagnostic or monitoring indicators of cardiovascular or metabolic complications in acromegaly.
format Article
id doaj-art-66d4e22ef4da4916a3044ed32dd17528
institution DOAJ
issn 2227-9059
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-66d4e22ef4da4916a3044ed32dd175282025-08-20T02:42:39ZengMDPI AGBiomedicines2227-90592025-03-0113366610.3390/biomedicines13030666Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary StudyMartyna Strzelec0Eliza Kubicka1Justyna Kuliczkowska-Płaksej2Katarzyna Kolačkov3Łucja Janek4Marek Bolanowski5Aleksandra Jawiarczyk-Przybyłowska6Department and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, PolandDepartment of Nuclear Medicine, Tadeusz Marciniak Lower Silesia Specialist Hospital-Centre for Medical Emergency, 54-049 Wroclaw, PolandDepartment and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, PolandDepartment and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, PolandStatistical Analysis Centre, Wroclaw Medical University, 50-368 Wroclaw, PolandDepartment and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, PolandDepartment and Clinic of Endocrinology and Internal Medicine, Wroclaw Medical University, Wybrzeże Pasteura 4, 50-367 Wroclaw, Poland<b>Background/Objectives:</b> Cardiovascular complications are a leading cause of premature mortality in patients with acromegaly. Copeptin (CPP) correlates strongly with plasma osmolality and is regulated by non-osmotic stimuli involved in the pathophysiology of cardiovascular disease. Mid-regional proadrenomedullin (MR-proADM), synthesized mainly in the adrenal medulla, vascular endothelial cells, and the heart, has vasodilatory effects. The study aimed to assess two cardiovascular biomarkers (CPP and MR-proADM) in acromegaly patients in relation to disease activity and compare findings with a control group. <b>Methods:</b> The study examined CPP and MR-proADM levels alongside hormonal and biochemical parameters and cardiovascular and metabolic disease prevalence in 53 acromegaly patients and 26 controls. <b>Results:</b> No significant differences in CPP or MR-proADM concentrations were observed between the two groups. However, a positive correlation occurred between growth hormone (GH) and CPP concentrations, and there was a negative correlation between fasting glucose and CPP concentrations in acromegaly patients. The study also found a positive correlation between low-density lipoprotein (LDL) cholesterol and MR-proADM concentrations and between high-density lipoprotein (HDL) cholesterol and MR-proADM levels in the study group. Moreover, atherogenic dyslipidemia was significantly more common in the active form of acromegaly and pituitary macroadenoma patients than in the control group. Acromegaly patients had significantly higher fasting glucose and fasting insulin levels compared to controls, and the homeostasis model assessment of the insulin resistance (HOMA-IR) index was significantly lower in the study group than in the controls. <b>Conclusions:</b> Neither CPP or MR-proADM are significant diagnostic or monitoring indicators of cardiovascular or metabolic complications in acromegaly.https://www.mdpi.com/2227-9059/13/3/666acromegalycardiovascular diseasescopeptinmid-regional proadrenomedullin
spellingShingle Martyna Strzelec
Eliza Kubicka
Justyna Kuliczkowska-Płaksej
Katarzyna Kolačkov
Łucja Janek
Marek Bolanowski
Aleksandra Jawiarczyk-Przybyłowska
Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
Biomedicines
acromegaly
cardiovascular diseases
copeptin
mid-regional proadrenomedullin
title Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
title_full Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
title_fullStr Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
title_full_unstemmed Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
title_short Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly—A Preliminary Study
title_sort copeptin and mid regional proadrenomedullin are not useful biomarkers of cardiometabolic disease in patients with acromegaly a preliminary study
topic acromegaly
cardiovascular diseases
copeptin
mid-regional proadrenomedullin
url https://www.mdpi.com/2227-9059/13/3/666
work_keys_str_mv AT martynastrzelec copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT elizakubicka copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT justynakuliczkowskapłaksej copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT katarzynakolackov copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT łucjajanek copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT marekbolanowski copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy
AT aleksandrajawiarczykprzybyłowska copeptinandmidregionalproadrenomedullinarenotusefulbiomarkersofcardiometabolicdiseaseinpatientswithacromegalyapreliminarystudy